4 studies found for:    parp prostate cancer | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
parp prostate cancer | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer
Condition: Metastatic Castration-resistant Prostate Cancer
Interventions: Drug: Olaparib;   Drug: Placebo;   Drug: Abiraterone;   Drug: Prednisone or prednisolone
2 Recruiting Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Conditions: Advanced or Recurrent Solid Tumors;   Breast Neoplasms;   Ovarian Cancer, Epithelial;   Ewing Sarcoma;   Small Cell Lung Carcinoma;   Prostate Cancer;   Pancreas Cancer
Intervention: Drug: BMN 673
3 Recruiting Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Hereditary Breast/Ovarian Cancer (BRCA1, BRCA2);   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Recurrent Prostate Cancer;   Triple-negative Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
4 Recruiting Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Conditions: Advanced Ovarian Cancer;   Primary Peritoneal Cancer;   Advanced Breast Cancer;   Advanced Solid Tumors
Intervention: Drug: BMN 673

Indicates status has not been verified in more than two years